Quimica Sintetica, S.a.

Wyeth

Zambon Group S.p.a.

Dipharma S.p.a.

Dipharma Francis S.r.l.

Chemo Iberica, S.a.

American Home Products Corporation

Bracco International Bv

Dinamite Dipharma S.p.a.

Zamon Group S.p.a.

Chemo Research, S.l.

Giuseppe Barreca

Pietro Allegrini

Vincenzo Cannata

Luca Carcone

Graziano Castaldi

Marcello Rasparini

Giovanni Marras

Giorgio Soriato

Domenico Magrone

Livius Cotarca

Gabriele Razzetti

Massimo Verzini

Maurizio Taddei

Alberto Bologna

Roberto Brescello

Fabio Morana

Paolo Andreella

Fabio Bassan

Norberto Masciocchi

Francesco Tasinato

Marco Demo

Claudio Giordano

Marco Villa

Silvio Iera

Alessandro Restelli

Michel Bernatchez

Damian Mark Grainger

Laura Russo

Renzo Rossi

Gaetano Marchioro

Gianpiero Ventimiglia

Elena Cini

Pierre Giguere

Roberto Rocco Tufaro

Samantha Louise Staniland

Bruno Romanò

Claudio Cianferotti

Elena Rossi

Andrea Poggiali

Corrado Velgi

Huang Liming

Giampiero Ventimiglia

Bruno Gaetano Romano

Marco Maria Gatti

Bruno Gaetano Romano'

Huan Liming

A highly pure form of ferric citrate and an industrially viable and advantageous process for its preparation are described.

Process for the preparation of ferric organic compounds

Industrially viable and advantageous processes for the preparation of Ozanimod are described. The invention also discloses the intermediates obtained in the process. 

Process for the preparation of sphingosine-1-phosphate receptor agonist

It is described an industrially viable and advantageous process for the preparation of (S)-beta-aminosulfone (1) starting from the corresponding racemic compound, said (S)-beta-aminosulfone being a useful intermediate for the preparation of N-(2-((1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl)acetamide, also known as Apremilast, the latter being suitable for use in methods of treating, preventing and/or managing psoriasis or psoriatic arthritis. 

Resolution of racemic beta-aminosulfone compounds

Novel crystalline forms of Eluxadoline, having the formula (I), are described. Also described are the processes for the preparation of said crystalline forms. 

Eluxadoline crystalline forms and processes for their preparation

It is described an industrially viable and advantageous process for the preparation of racemic beta-aminosulfone (1), an useful intermediate for the preparation of N-(2-((1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl)acetamide, also known as Apremilast, the latter being suitable for use in methods of treating, preventing and/or managing psoriasis or psoriatic arthritis.

Racemic beta-aminosulfone compounds

The invention relates to an industrially viable and advantageous process for the preparation of (2S,3 R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid, having the following formula (I) generally known as Droxidopa, or of intermediates useful in the synthesis thereof. 

Processes for the preparation of diastereomerically and enantiomerically enriched oxazolines

Two processes are described for preparing, in different diastereomeric purity degrees, the compound (S)-isopropyl-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)-phosphoryl)amino) propanoate, having the formula given below, known as Sofosbuvir and used for the treatment of hepatitis C. 

Nucleoside phosphoramidates useful for the treatment of viral infections and preparation thereof

The invention relates to a process for the preparation of Levomilnacipran or salts thereof, compounds useful in the treatment of depression, with high yield.

Process for the preparation of (1S,2R)-Milnacipran

It is described a process for the opening of lactone or lactam rings useful in the synthesis of pharmaceutically active compounds and the intermediates thereof, particularly Aliskiren. It has found that by selecting a type of solvent it is possible to obtain excellent yields and high optical and chemical purity of the isolated products.

Chemical process for opening ring compounds

Are disclosed new crystalline forms of asenapine maleate, useful in the production of pharmaceutical formulations for the treatment of diseases of the central nervous system, in particular schizophrenia; processes for the production of these new crystalline forms are also disclosed.

Polymorphic forms of asenapine maleate and processes for their preparation

The present invention relates to methods of preparing polymorphic Form A of bazedoxifene acetate and polymorphic Form A prepared by such methods.

Methods of preparing polymorphic form A of bazedoxifene acetate

Novel crystalline hydrate form of (S)-1-phenylethylammonium (R)-diphenyl-methanesulphinyl-acetate and its use in a process for the preparation of (R)-benzhydrylsulphinylacetamide.

Crystalline form of (S)-1-phenylethylammonium (R)-diphenylmethanesulphinyl-acetate

Rabeprazole sodium in the monohydrate crystalline form, pharmaceutical compositions thereof, the use thereof in therapy, a process for its preparation, and the use thereof for the purification of rabeprazole sodium.

Crystalline form of rabeprazole sodium

A process for the preparation of telmisartan (I) and novel intermediates useful for its synthesis. 

Process for the preparation of telmisartan

Growing community of inventors

Montevecchia, Italy

Giuseppe Barreca